On a molecular level, amplification of the proto-oncogene human epidermal growth factor receptor 2 (HER2) is detected in roughly one in six gastric adenocarcinomas, offering a rationale for targeted therapy in that subset [13]. This evidence concerns the gene ERBB2 and gastric adenocarcinoma.